title: Differences in binding properties of mu and delta opioid receptor subtypes from rat brain: kinetic analysis and effects of ions and nucleotides.
abstract: Differences in binding properties of mu and delta opioid receptors were investigated using DAGO (Tyr-D-Ala-Gly-MePhe-Gly-ol) and DTLET (Tyr-D-Thr-Gly-Phe-Leu-Thr), which occur, respectively, as the most selective mu and delta radioligands available. At high concentration, each agonist is able to interact with its nonspecific sites. Competition experiments indicated that a two-site competitive model was adequate to explain the interactions of DAGO and DTLET with [3H]DTLET and [3H]DAGO binding sites, respectively. The weak cross-reactivity (congruent to 10%) of DTLET for mu sites was taken into account in these experiments. On the other hand, DAGO and DTLET exhibit differential binding kinetics. Thus, at 35 degrees C, the lifetime of DTLET within its receptor site is about 14 times longer than that of the mu agonist. Sodium and manganese ions decrease the maximal number of high affinity mu and delta sites, but the sensitivity of mu receptors is three times higher towards Na+ and 20-fold higher towards Mn2+ than that of delta receptors. GTP reduces similarly the mu and delta binding whereas only the DAGO binding was modified by the nonhydrolyzable analogue guanylylimidodiphosphate [GMP-P(NH)P]. However, in the presence of Na+ ions, GMP-P(NH)P inhibits the DTLET binding in a concentration-dependent manner. The effects of Na+ and GMP-P(NH)P could be explained by a sequential transformation of delta receptors to low-affinity states. This model predicts that Na+, by lowering the affinity of a fraction of sites, produces a decrease in the maximal number of high-affinity delta receptors and that GMP-P(NH)P enhances the Na+ effect. Moreover, the binding kinetic to this high-affinity state was also modified by Na+ and nucleotides. All of these data support the existence of two independent mu and delta binding sites, the properties of which are differentially regulated by these endogenous effectors.
authors.forename: J M
authors.initials: JM
authors.lastname: Zajac
authors.forename: B P
authors.initials: BP
authors.lastname: Roques
mesh_terms: D000494:Allosteric Regulation; D000818:Animals; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism*; D007700:Kinetics; D008345:Manganese / Q000494:pharmacology; D009711:Nucleotides / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000378:metabolism*; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D012964:Sodium / Q000494:pharmacology; D013329:Structure-Activity Relationship; D013574:Synaptosomes / Q000378:metabolism
chemical_list: D009711:Nucleotides; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; D008345:Manganese; D012964:Sodium